Alector (ALEC) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alector (ALEC) has outperformed Tectonic Therapeutic (TECX) over the past year, gaining 88.3% versus a gain of 8.1%. Over five years, TECX leads with a -57.7% price change compared with -88.3% for ALEC. Tectonic Therapeutic is the larger company by market cap ($405.3 million vs $347.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | TECX |
|---|---|---|
| Share price | $2.34 | $20.73 |
| Market cap | $347.63M | $405.26M |
| 1-day change | +1.52% | -1.47% |
| YTD return | +49.68% | -0.62% |
| 1-year return | +88.31% | +8.08% |
| 5-year return | -88.28% | -57.66% |
| P/E ratio (TTM) | 6.31 | — |
| EPS (TTM) | $0.37 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $21.05M | — |
| Revenue growth (YoY) | -79.07% | — |
| Net income (latest FY) | $-142.93M | $-74.15M |
| Operating margin | -741.30% | — |
| Net margin | -679.16% | — |
| 52-week high | $2.84 | $39.53 |
| 52-week low | $1.09 | $16.77 |
| Distance from 52-week high | -17.78% | -47.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +89.29% | +242.50% |
| Average volume | 3.34M | 212.16K |
| Shares outstanding | 148.88M | 19.55M |
| Employees | 103 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed TECX by 80.2 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
ALEC vs TECX FAQ
Which is bigger, Alector or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $405.26M compared with $347.63M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or TECX?
ALEC returned +88.31% over the past 12 months, compared with +8.08% for TECX (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.